Plus Therapeutic (Cytory)
Verluste heute mit +250% belohnt
Q2 2019 net loss from continuing operations was -$2.3 million,
or -$5.12 per share. Q2 2019 total net loss after factoring in
discontinued operations was -$9.1 million, or $20.67 per share.
Operating cash burn for Q2 was approximately $1.6 million.
Plus Therapeutics ended Q2 with approximately $4.5 million
of cash and cash equivalents.
Aktien insgesamt: 443000 (angeblich!)
Tiefstkurs: $3,80 nach R-Split
Höchstkurs: $15,35 -16:22 Time (MEZ)
Buy: $4,00
SELL: $14,88
Volumen: 30K
Plus 270%
S F
(Verkleinert auf 69%)

